Cargando…

Efficacy and tolerability balance of oxycodone/naloxone and tapentadol in chronic low back pain with a neuropathic component: a blinded end point analysis of randomly selected routine data from 12-week prospective open-label observations

OBJECTIVE: To evaluate the benefit–risk profile (BRP) of oxycodone/naloxone (OXN) and tapentadol (TAP) in patients with chronic low back pain (cLBP) with a neuropathic component (NC) in routine clinical practice. METHODS: This was a blinded end point analysis of randomly selected 12-week routine/ope...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ueberall, Michael A, Mueller-Schwefe, Gerhard H H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5115682/ https://www.ncbi.nlm.nih.gov/pubmed/27881925 http://dx.doi.org/10.2147/JPR.S112418

Ejemplares similares

Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice
por: Ueberall, Michael A, et al.
Publicado: (2016)

Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids
por: Ueberall, Michael A, et al.
Publicado: (2015)

Methodological Issues on a Clinical Trial to Test Tapentadol Prolonged release vs. Oxycodone/Naloxone Prolonged release
por: Bacallao, Jorge, et al.
Publicado: (2016)

Tapentadol and Oxycodone/Naloxone Prescribing Patterns in Primary Health Care in Catalonia, Spain: A Cross-Sectional Study
por: Viñas-Bastart, Montserrat, et al.
Publicado: (2021)

Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study
por: Barrachina, Jordi, et al.
Publicado: (2022)

Sex Differences in Oxycodone/Naloxone vs. Tapentadol in Chronic Non-Cancer Pain: An Observational Real-World Study
por: Barrachina, Jordi, et al.
Publicado: (2022)

Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: analysis of 12-week open-label real-world data provided by the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2019)

Effectiveness, Safety, and Tolerability of Nabiximols Oromucosal Spray vs Typical Oral Long-Acting Opioid Analgesics in Patients with Severe Neuropathic Back Pain: Analysis of 6-Month Real-World Data from the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2021)

Tapentadol vs oxycodone/naloxone in the management of pain after total hip arthroplasty in the fast track setting: an observational study
por: D’Amato, Tiziana, et al.
Publicado: (2019)

Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone
por: Haeseler, Gertrud, et al.
Publicado: (2017)

Physicians Experience with and Expectations of the Safety and Tolerability of WHO-Step III Opioids for Chronic (Low) Back Pain: Post Hoc Analysis of Data from a German Cross-Sectional Physician Survey
por: Ueberall, Michael A., et al.
Publicado: (2015)

Comparison of the Effectiveness and Tolerability of Nabiximols (THC:CBD) Oromucosal Spray versus Oral Dronabinol (THC) as Add-on Treatment for Severe Neuropathic Pain in Real-World Clinical Practice: Retrospective Analysis of the German Pain e-Registry
por: Ueberall, Michael A, et al.
Publicado: (2022)

The place of oxycodone/naloxone in chronic pain management
por: Leppert, Wojciech
Publicado: (2013)

Tapentadol shows lower intrinsic efficacy at µ receptor than morphine and oxycodone
por: Manandhar, Preeti, et al.
Publicado: (2022)

Analgesic effectiveness and tolerability of oral oxycodone/naloxone and pregabalin in patients with lung cancer and neuropathic pain: an observational analysis
por: De Santis, Stefano, et al.
Publicado: (2016)

Comparison of Real-world Outcomes Between Patients Treated with Tapentadol ER or Oxycodone CR
por: Durkin, Mike, et al.
Publicado: (2015)

Tapentadol for neuropathic pain: a review of clinical studies
por: Freo, Ulderico, et al.
Publicado: (2019)

Opioid-Induced Bowel Dysfunction in Patients Undergoing Spine Surgery: Comparison of Oxycodone and Oxycodone-Naloxone Treatment
por: Kokki, Merja, et al.
Publicado: (2016)

Treatment of Opioid Withdrawal Syndrome Triggered by Oxycodone/Naloxone with Dexmedetomidine
por: Go, Se-Il, et al.
Publicado: (2023)

Web-Based Discussion and Illicit Street Sales of Tapentadol and Oxycodone in Australia: Epidemiological Surveillance Study
por: Black, Joshua, et al.
Publicado: (2021)

Efficacy, tolerability, and safety of an oral enzyme combination vs diclofenac in osteoarthritis of the knee: results of an individual patient-level pooled reanalysis of data from six randomized controlled trials
por: Ueberall, Michael A, et al.
Publicado: (2016)

Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis
por: Lazzari, Marzia, et al.
Publicado: (2015)

Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350
por: Poulsen, Jakob L, et al.
Publicado: (2018)

Influence of tapentadol and oxycodone on the spinal cord and brain using electrophysiology: a randomized, placebo‐controlled trial
por: Nedergaard, Rasmus Bach, et al.
Publicado: (2022)

Tapentadol: an effective option for the treatment of back pain
por: Coluzzi, Flaminia, et al.
Publicado: (2019)

Tapentadol extended release in the management of peripheral diabetic neuropathic pain
por: Vadivelu, Nalini, et al.
Publicado: (2015)

Treatment of Failed Back Surgery Syndrome in a Forty-Three-Year-Old Man With High-Dose Oxycodone/Naloxone
por: Bujedo, Borja Mugabure
Publicado: (2015)

Pain therapy with oxycodone/naloxone prolonged-release combination: case report
por: Błaszczyk, Feliks, et al.
Publicado: (2013)

Intractable restless legs syndrome: role of prolonged-release oxycodone–naloxone
por: de Biase, Stefano, et al.
Publicado: (2016)

Comparison of the Risks of Shopping Behavior and Opioid Abuse Between Tapentadol and Oxycodone and Association of Shopping Behavior and Opioid Abuse
por: Cepeda, M. Soledad, et al.
Publicado: (2014)

Abuse Potential of Intravenous Oxycodone/Naloxone Solution in Nondependent Recreational Drug Users
por: Colucci, Salvatore V., et al.
Publicado: (2014)

Combined Administration of Oxycodone/Naloxone in Chronic Osteo-Articular Diseases Pain Therapy
por: Rosa, Palomba, et al.
Publicado: (2014)

Developments in managing severe chronic pain: role of oxycodone–naloxone extended release
por: Fanelli, Guido, et al.
Publicado: (2015)

Prediction of response to tapentadol in chronic low back pain
por: Reimer, M., et al.
Publicado: (2016)

Tapentadol: an effective option for the treatment of back pain [Corrigendum]
Publicado: (2019)

Effects of dextromethorphan and oxycodone on treatment of neuropathic pain in mice
por: Yang, Pao-Pao, et al.
Publicado: (2015)

Outcomes Associated with Treatment of Chronic Pain with Tapentadol Compared with Morphine and Oxycodone: A UK Primary Care Observational Study
por: Morgan, Christopher Ll., et al.
Publicado: (2019)

Long-term efficacy and safety of oxycodone–naloxone prolonged release in geriatric patients with moderate-to-severe chronic noncancer pain: a 52-week open-label extension phase study
por: Guerriero, Fabio, et al.
Publicado: (2016)

Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial
por: Leng, Xiaomei, et al.
Publicado: (2020)

Oxycodone/Naloxone: Role in Chronic Pain Management, Opioid-Induced Constipation, and Abuse Deterrence
por: DePriest, Anne Z., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_qu5kga69gfit2a117f3514delu